India: Cipla, Aurobindo Pharma acquire products divested by Teva in US

Visual from Cipla website

Cipla Ltd, India’s fifth largest drug maker, on Thursday announced that it has acquired a portfolio of three products from Teva Pharmaceutical Industries Ltd in the US, which are being divested by the Israel-based company as a precondition to its $40.5 billion acquisition of Allergan Plc’s generic business.

The spokesperson for Cipla confirmed the purchase without disclosing financial and product details.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter